Development and Commercialization Partners

Our decision to selectively partner our proprietary technology has validated our investment in suprachoroidal delivery using our

SCS Microinjector® and has expanded our overall development pipeline.

regenx logo

REGENXBIO has exclusive worldwide rights to our SCS Microinjector for delivery of adeno-associated virus (AAV)-based gene therapy to the suprachoroidal space to treat wet AMD, diabetic retinopathy and other conditions for which anti-VEGF treatment is the standard of care.

Aura Biosciences has a worldwide licensing agreement for the use of our Suprachoroidal Space (SCS) Microinjector to deliver their proprietary drug candidates into the SCS for the potential treatment of certain ocular cancers, including choroidal melanoma.

aura logo


XIPERE™ (triamcinolone acetonide suprachoroidal injectable suspension)

We have completed attractive licensing agreements with ideal partners for the commercialization and further development of XIPERE.

Bausch Health has an exclusive commercialization and development license for XIPERE in the U.S. and Canada, as well as exclusive options for the right to commercialize and develop XIPERE in (i) Europe and the United Kingdom, (ii) Australia and New Zealand, and (iii) South America and Mexico.

Arctic Vision has an exclusive license to develop and commercialize XIPERE for indications associated with uveitis in Greater China (mainland China, Hong Kong, Macau and Taiwan) and South Korea. They also have the right to develop and commercialize XIPERE for additional ophthalmic indications in Greater China and South Korea, with consent from Clearside.

To learn more about our programs and potential business development opportunities, please contact

Rick McElheny, VP, Business Development at rick.mcelheny@clearsidebio.com.